Rheumatoid Arthritis Treatment Market 2026 - Views Sought On New Approach

Rheumatoid Arthritis Treatment Market Size,
Share, Trend, Outlook, Future Analysis And
Synthesis By 2026
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S.
citizens (American College of Rheumatology). More surprising is to know that around 75% of this
affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed
early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand
and feet tend to be affected the most. Treatments available for rheumatoid arthritis aids to relive
symptoms and improve the joint function. A comprehensive treatment for RA usually involves integration
of patient education, exercise, medications, and surgery (occasionally). The rheumatoid arthritis
treatment market can be analyzed based on the drug type, as follows:
Biological drugs:
• Monoclonal antibodies
• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Analgesics
• Disease-modifying anti-rheumatic drugs (DMARDs)
- IL-6 inhibitors
- TNF inhibitors
Download PDF Brochure of This Research Report @
NSAIDs and corticosteroid are also the first-line fast acting therapeutic drugs. Acetylsalicylate,
naproxen, ibuprofen, etodolac, and diclofenac are the NSAIDs usually prescribed as first-line
drugs for RA. These drugs reduce inflammation, and pain. Corticosteroid medications are given
either orally or parenterally to reduce inflammation and restore joint mobility and function.
These class of drugs are more potent than NSAIDs and therefore usually preferred a first line
therapy by prescribers. The global rheumatoid arthritis treatment industry is expected to be
driven considerably in near future by DMARDs that form second line slow-acting therapeutic
drugs. Longer therapeutic regimen with these drugs increases cost of therapy and also promote
remission of joint destruction and deformity. Methotrexate is the most commonly prescribed
second line drug for RA and hence, occupies major share in the respective segment of global
rheumatoid arthritis treatment market. Tofacitinib (Xeljanz) is the most potential FDA approved
Janus kinase (JAK) inhibitor available in the global market of rheumatoid arthritis treatment.
Report includes chapters which deeply display the following deliverable about industry :
• Rheumatoid Arthritis Treatment Market Research Objective and Assumption
• Rheumatoid Arthritis Treatment Market Purview - Report Description, Executive Summary,
and Coherent Opportunity Map (COM)
• Rheumatoid Arthritis Treatment Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Rheumatoid Arthritis Treatment Market, By Regions
• Rheumatoid Arthritis Treatment Market Competition by Manufacturers including Production,
Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Rheumatoid Arthritis Treatment Market Manufacturers Profiles/Analysis including Company
Basic Information, Manufacturing Base and Its Competitors.
• Rheumatoid Arthritis Treatment Market Manufacturing Cost Analysis including Key Raw
Materials and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Rheumatoid Arthritis Treatment Market Forecast including Production, Consumption, Import
and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Key statistics pertaining to the global rheumatoid arthritis treatment market:
Over time, there is damage to cartilage and mobility function of the affected joint in rheumatoid
arthritis patient.
• Affects nearly 1.3 million U.S. population (RheumatoidArthritis.org)
• Most common in the age group of 30-60 years
• Global prevalence varies in the range of 0.3% to 1% (World Health Organization)
• Average annual cost of treatment may go up to US $20,000 (RheumatoidArthritis.org)
• According to the Arthritis Foundation, people with RA loose more workdays compared to those
affected by any other medical condition
• According to a Harvard University study published in the Journal of Global Health (2017), prevalence
of rheumatoid arthritis in Southeast Asian countries was 0.4%, 0.42 in western Pacific region, and 0.37%
in eastern Mediterranean countries
Global Key Players
Some of the major players in the global rheumatoid arthritis treatment market are Pfizer, Inc., Johnson
& Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,
Grab Best Discount on This Research Report @ https://www.coherentmarketinsights.com/insight/
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology).